Episode
Episode 449: Putting People Affected by MS at the Center of MS Research with Sara Loud, Stephanie Buxhoeveden, and Hollie Schmidt
- Podcast
- RealTalk MS
- Published
- Apr 6, 2026
- Duration seconds
- 2277
- Processing state
not_requested- Canonical source
- https://realtalkms.com/449
Actions
POST https://stenobird.com/v1/public/podcasts/realtalk-ms-779631/episodes/episode-449-putting-people-affected-by-ms-at-the-center-of-ms-research-with-sara-loud-stephanie-buxhoeveden-and-hollie-schmidt/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/realtalk-ms-779631/episode-449-putting-people-affected-by-ms-at-the-center-of-ms-research-with-sara-loud-stephanie-buxhoeveden-and-hollie-schmidt.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
When you join the iConquer MS community, you're no longer just a patient; you become a research partner. Not just a data point in someone's study. You become the person to suggest the study, to help define the study, and to participate in sharing the outcome of the study. In this week's episode, I talk with the iConquer MS leadership team about what it means to be part of this people-powered research revolution and how iConquer MS keeps people affected by MS at the center of MS research. The National Institutes of Health has just published a Strategic Plan for Disability Health Research. We're sharing all the details. And a research team analyzed data from 20 global studies to determine whether anti-CD20 disease-modifying therapies (Ocrevus, Kesimpta, Briumvi) were cost-effective. We're sharing their somewhat surprising results. And a research team analyzed data from 20 global studies to determine whether anti-CD20 disease-modifying therapies (Ocrevus, Kesimpta, Briumvi) were cost-effective. We're sharing their somewhat surprising results. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: We're talking about people-powered MS research :22 The NIH has published a Strategic Plan for Disability Health Research 1:15 Researchers determine whether anti-CD20 disease-modifying therapies (Ocrevus, Kesimpta, Briumvi) are cost-effective 6:05 Sara Loud, Stephanie Buxhoeveden, and Hollie Schmidt discuss what it means to put people affected by MS at the center of MS research 12:41 Share this episode 36:26 Next week 36:45 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/449 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your oppor…